- Coordinator
- Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
- Runs
- 1 April 2023 to 31 March 2028
- Status
- Running
- EU funding
- €23.0m
- Total cost
- €36.2m
- Partners
- 39 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101112135
What the project is doing
In the project's own words, from its summary on CORDIS.
IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced regulatory and HTA decision-making recommendations for integrated health research, with the aim to improve care and better meet the needs of patients and health care professionals. The IDERHA open platform for multi-modal health data will enhance innovation in EU health care systems and is directly scalable by means of connecting additional systems, data sources and additional services and tools.
It will extend and elaborate standards in semantic interpretation, data quality, ethics and transferability to ensure the harmonisation of heterogeneous data sources and wider health data reuse. Use cases positioned along the lung cancer patient pathway will be implemented using retrospective data and in a remote patient care context. These practical implementations will demonstrate the added value of multi-modal data aggregation and analysis with impacts expected on public health, patient burden, health outcomes and cost.
We will perform AI/ML based lung-cancer risk profiling using patient`s EHRs, and improved CT image- based AI/ML to provide risk prediction of potential lung cancer patients, and explore the possibilility of personal prognosis of disease progression. Using patient monitoring and engagement, including digital biomarker, PROMs, and connected devices, the IDERHA platform will enable remote patient monitoring, and provide data for joint patient-health professional decision making.
Along with health care stakeholders, IDERHA will develop consensus policy recommendations for appropriate data sharing to enable multi-stakeholder research. Informed by Patient Advisory Groups, we will address critical obstacles and issues to heterogeneous health data primary and secondary use. Regulatory and HTA agencies will be engaged to create criteria for assessing the acceptability of heterogeneous health research results in regulatory and HTA decision-making.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Coordinator |
| Fachhochschule Technikum Wien | Wien | Austria | Participant |
| Ludwig Boltzmann Gesellschaft Osterreichische Vereinigung Zur Forderung Der Wissenschaftlichen Forschung | Wien | Austria | Participant |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| European Cancer Patient Coalition | Bruxelles / Brussel | Belgium | Participant |
| Fortrea Belgium | Bruxelles / Brussel | Belgium | Participant |
| Forum Des Patients Europeens | Bruxelles / Brussel | Belgium | Participant |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| Johnson & Johnson Medical NV | Machelen | Belgium | Participant |
| Q1.6 BV | Antwerpen | Belgium | Participant |
| The European Institute for Innovation Through Health Data | Gentbrugge | Belgium | Participant |
| European Respiratory Society | Lausanne | Switzerland | Associatedpartner |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Hygiaso AG | Basel | Switzerland | Associatedpartner |
| Lung Cancer Europe Luce | Bern | Switzerland | Associatedpartner |
| Takeda Pharmaceuticals International AG | Glattpark | Switzerland | Participant |
| Asklepios Kliniken Hamburg GmbH | Hamburg | Germany | Participant |
| Janssen-Cilag GmbH | Neuss | Germany | Third party |
| Johnson & Johnson Medical GmbH | Norderstedt | Germany | Participant |
| Klinikum Der Technischen Universität München (tum Klinikum) | Muenchen | Germany | Participant |
| Msb Medical School Berlin GmbH | Berlin | Germany | Participant |
| Laegemiddelstyrelsen | Kobenhavn S | Denmark | Participant |
| Region Midtjylland | Viborg | Denmark | Participant |
| Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Sevilla | Spain | Third party |
| Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana | Valencia | Spain | Participant |
| Servicio Andaluz De Salud | Sevilla | Spain | Participant |
| Servizo Galego De Saude | Santiago De Compostela | Spain | Participant |
| Teknologian Tutkimuskeskus VTT Oy | Espoo | Finland | Participant |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Participant |
| Information Technology for Translational Medicine (ittm) SA | Esch-Uelzecht | Luxembourg | Participant |
| Universite Du Luxembourg | Esch-Sur-Alzette | Luxembourg | Participant |
| Janssen Vaccines & Prevention BV | Leiden | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Participant |
| Philips Medical Systems Nederland BV | Best | Netherlands | Participant |
| Stichting Lygature | Utrecht | Netherlands | Participant |
| Janssen Cilag Limited | High Wycombe | United Kingdom | Third party |
| Labcorp Early Development Laboratories Limited | Harrogate | United Kingdom | Participant |
| National Institute for Health and Care Excellence | Manchester | United Kingdom | Associatedpartner |
| Medical Device Business Services Inc | Warsaw | United States | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI